Developer docs
API playgroundTry for free, no card

Search company profiles

Alector

Full company profile

uuid0002dp1

Namestring
Alector
Legal namestring
Alector, Inc.
Websiteurl
alector.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Alector, Inc. is a publicly traded clinical-stage biotechnology company (NASDAQ: ALEC) founded in 2013 and headquartered in South San Francisco, California. The company develops immuno-neurology therapies for neurodegenerative diseases, with a pipeline targeting frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. Alector combines human genetics, neuroscience, and immunology expertise to develop antibody and siRNA-based therapeutic candidates designed to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Its core technology foundation is the proprietary Alector Brain Carrier (ABC) platform, which uses receptor-mediated transcytosis to deliver therapeutic agents across the blood-brain barrier.

The pipeline included latozinemab (AL001), a progranulin-elevating antibody for FTD-GRN that received FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations; AL101 (nivisnebart), developed with GSK for Alzheimer's disease; and AL002, a TREM2 agonistic antibody developed with AbbVie. The preclinical pipeline leverages ABC technology across multiple modalities including anti-amyloid antibodies, anti-tau siRNA, GCase enzyme replacement, and anti-alpha-synuclein siRNA. Latozinemab received Breakthrough Therapy Designation from the FDA in 2025.

Alector operates as a pre-revenue biotech, generating collaboration revenue rather than product sales through co-development partnerships with GSK ($700 million upfront in 2021) and AbbVie. The company is publicly listed on NASDAQ following its 2019 IPO and subsequent financings including a $75 million public offering in January 2024 and a $50 million debt facility from Hercules Capital in November 2024. The company has suffered multiple clinical trial setbacks in 2025-2026, including the Phase 3 INFRONT-3 failure for latozinemab (October 2025) and the Phase 2 PROGRESS-AD termination for AL101 (April 2026), prompting a 49% workforce reduction and a market capitalization decline to approximately $135 million by December 2025.

Short descriptiontext

Alector is a publicly traded clinical-stage biotechnology company developing immuno-neurology antibody therapies and siRNA candidates for neurodegenerative diseases, including frontotemporal dementia, Alzheimer's disease, and Parkinson's disease, using its proprietary ABC blood-brain barrier delivery platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurodegenerative disease therapeutics, immuno-neurology drug development, monoclonal antibody pipeline, blood-brain barrier delivery, clinical-stage biotechnology
Industry1 code
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Neurodegenerative Disease Therapeutics / Immuno-Neurology Biotechnology
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. Developing pipeline of therapeutic candidates for neurodegenerative diseases. Revenue will come from product sales upon regulatory approval. Currently no commercial products.

alector.com
2Collaborative Development Agreements
TypeLicensing Royalties
Description

Partnership with GSK for co-development and co-commercialization of progranulin franchise programs (AL001 and AL101). Partnership with AbbVie for co-development of AL002. These partnerships provide upfront payments, milestone payments, and potential royalties.

alector.com
3Public Equity Offerings
TypeOne Time License
Description

Raised approximately $75 million through public offering of common stock in January 2024 (10.87 million shares). Conducted under shelf registration with SEC.

investors.alector.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Alector is a clinical-stage biotechnology company that discovers and develops biologic therapeutics—including monoclonal antibodies, siRNA candidates, and enzyme replacement therapies—for neurodegenerative diseases such as frontotemporal dementia (FTD-GRN), Alzheimer's disease, Parkinson's disease, and Lewy body dementia. The pipeline is enabled by the proprietary Alector Brain Carrier (ABC) technology, which delivers therapeutic agents across the blood-brain barrier using receptor-mediated transcytosis. The company co-develops and co-commercializes its programs through partnerships with major pharmaceutical companies including GSK and AbbVie.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Latozinemab increased plasma progranulin levels in FTD-GRN patients (Phase 3 INFRONT-3 trial)
+5 more records
Product overview1 text field

Alector is a clinical-stage biotechnology company developing a pipeline of biologic drug candidates for neurodegenerative diseases. The company's product portfolio centers on immuno-neurology therapeutics targeting genetic pathways involved in neurodegeneration, including progranulin-elevating antibodies (latozinemab/AL001 and AL101), TREM2 agonistic antibodies (AL002), and next-generation candidates leveraging the proprietary Alector Brain Carrier (ABC) technology for enhanced blood-brain barrier delivery. The ABC platform supports multiple modality types including antibodies, siRNAs, and enzyme replacement therapies applied across Alzheimer's disease, frontotemporal dementia, Parkinson's disease, and other neurological conditions. Alector's clinical-stage candidates include latozinemab (AL001) for FTD-GRN and AL101 for Alzheimer's disease (with GSK partnership), while the preclinical pipeline features programs like AL037/AL137-ABC (anti-amyloid beta), AL050-ABC (GCase enzyme replacement), and siRNA-based programs targeting tau, alpha-synuclein, and NLRP3.

Product and service9 records
1Latozinemab (AL001)
CategoryClinical-stage drug candidate
Description

Progranulin-elevating monoclonal antibody designed to restore diminished progranulin protein levels to normal ranges in patients with frontotemporal dementia due to GRN gene mutations (FTD-GRN), with the goal of slowing disease progression. Targeted at patients with this rare, rapidly progressing form of dementia.

2AL101 (Nivisnebart / GSK4527226)
CategoryClinical-stage drug candidate
Description

Progranulin-elevating monoclonal antibody developed in collaboration with GSK for the treatment of early Alzheimer's disease, designed to increase progranulin levels in the brain as a potential strategy for slowing neurodegeneration.

3AL002
CategoryClinical-stage drug candidate
Description

TREM2 agonistic antibody for early Alzheimer's disease developed in partnership with AbbVie, targeting neuroinflammation and microglia function to restore immune and nerve cell activity in the brain.

4AL037/AL137-ABC
CategoryPreclinical drug candidate
Description

Proprietary anti-amyloid beta (Aβ) antibody paired with the Alector Brain Carrier (ABC) for the treatment of Alzheimer's disease. Designed to remove brain amyloid plaques with potential to reduce ARIA risk and enable subcutaneous delivery.

5AL064/AL164-ABC
CategoryPreclinical drug candidate
Description

Anti-tau siRNA combined with the Alector Brain Carrier, targeting tau pathology in Alzheimer's disease and other tauopathies by inhibiting tau mRNA and protein synthesis.

6AL050-ABC
CategoryPreclinical drug candidate
Description

Engineered GCase enzyme replacement therapy paired with the Alector Brain Carrier for GBA gene mutation carriers with Parkinson's disease and Lewy body dementia, designed to break down glucocerebroside that accumulates in neurons.

7ADP062-ABC
CategoryResearch-stage drug candidate
Description

Anti-α-synuclein siRNA combined with the Alector Brain Carrier for Parkinson's disease, targeting α-synuclein pathology by inhibiting mRNA and protein synthesis.

8ADP065-ABC
CategoryResearch-stage drug candidate
Description

Anti-NLRP3 siRNA combined with the Alector Brain Carrier targeting NLRP3-driven neuroinflammation in Alzheimer's disease and Parkinson's disease.

9Alector Brain Carrier (ABC) technology platform
CategoryTechnology platform
Description

Proprietary blood-brain barrier technology platform using receptor-mediated transcytosis to enhance brain penetration of therapeutic agents, enabling delivery of antibodies, siRNAs, and enzyme replacement therapies to the brain for the treatment of neurodegenerative diseases.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Collaborative agreement with GSK to co-develop and co-commercialize progranulin franchise programs AL001 (latozinemab) and AL101. GSK paid $700 million upfront in 2021. Programs focused on treating frontotemporal dementia (FTD-GRN) and Alzheimer's disease by elevating progranulin levels.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Partnership formed with AbbVie to co-develop Alector's Alzheimer's-focused lead program AL002. AL002 is a TREM2 agonistic antibody for treatment of early Alzheimer's disease. The partnership leverages AbbVie's global pharmaceutical development and commercialization capabilities.

Strategic tierImportantTypeTechnology or IntegrationAnnounced on2015-01-01
Description

Strategic alliance with Adimab to access antibody technologies for drug discovery. This partnership provided Alector with access to Adimab's yeast-based antibody discovery platform, supporting the development of antibody therapeutics for neurodegenerative diseases.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Collaborative research agreement with Johnson & Johnson Innovation Center to fund one target through proof-of-concept in disease models. Part of Alector's early strategic partnerships to advance neurodegeneration research.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors26 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alector

Neurodegenerative Disease Therapeutics / Immuno-Neurology Biotechnologyalector.com

Alector is a publicly traded clinical-stage biotechnology company developing immuno-neurology antibody therapies and siRNA candidates for neurodegenerative diseases, including frontotemporal dementia, Alzheimer's disease, and Parkinson's disease, using its proprietary ABC blood-brain barrier delivery platform.

What Alector does

Alector, Inc. is a publicly traded clinical-stage biotechnology company (NASDAQ: ALEC) founded in 2013 and headquartered in South San Francisco, California. The company develops immuno-neurology therapies for neurodegenerative diseases, with a pipeline targeting frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. Alector combines human genetics, neuroscience, and immunology expertise to develop antibody and siRNA-based therapeutic candidates designed to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Its core technology foundation is the proprietary Alector Brain Carrier (ABC) platform, which uses receptor-mediated transcytosis to deliver therapeutic agents across the blood-brain barrier.

The pipeline included latozinemab (AL001), a progranulin-elevating antibody for FTD-GRN that received FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations; AL101 (nivisnebart), developed with GSK for Alzheimer's disease; and AL002, a TREM2 agonistic antibody developed with AbbVie. The preclinical pipeline leverages ABC technology across multiple modalities including anti-amyloid antibodies, anti-tau siRNA, GCase enzyme replacement, and anti-alpha-synuclein siRNA. Latozinemab received Breakthrough Therapy Designation from the FDA in 2025.

Alector operates as a pre-revenue biotech, generating collaboration revenue rather than product sales through co-development partnerships with GSK ($700 million upfront in 2021) and AbbVie. The company is publicly listed on NASDAQ following its 2019 IPO and subsequent financings including a $75 million public offering in January 2024 and a $50 million debt facility from Hercules Capital in November 2024. The company has suffered multiple clinical trial setbacks in 2025-2026, including the Phase 3 INFRONT-3 failure for latozinemab (October 2025) and the Phase 2 PROGRESS-AD termination for AL101 (April 2026), prompting a 49% workforce reduction and a market capitalization decline to approximately $135 million by December 2025.

Alector firmographics

Firmographics
Name
Alector
Legal name
Alector, Inc.
Website
https://alector.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Short description
Alector is a publicly traded clinical-stage biotechnology company developing immuno-neurology antibody therapies and siRNA candidates for neurodegenerative diseases, including frontotemporal dementia, Alzheimer's disease, and Parkinson's disease, using its proprietary ABC blood-brain barrier delivery platform.
Ownership category
akta.pro rank

Alector industry classification

Industry
Product category
Neurodegenerative Disease Therapeutics / Immuno-Neurology Biotechnology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Neurodegenerative disease therapeutics
  • Immuno-neurology drug development
  • Monoclonal antibody pipeline
  • Blood-brain barrier delivery
  • Clinical-stage biotechnology

Where Alector is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Alector business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical-stage biotech company. Developing pipeline of therapeutic candidates for neurodegenerative diseases. Revenue will come from product sales upon regulatory approval. Currently no commercial products.
  2. Collaborative Development Agreements: Partnership with GSK for co-development and co-commercialization of progranulin franchise programs (AL001 and AL101). Partnership with AbbVie for co-development of AL002. These partnerships provide upfront payments, milestone payments, and potential royalties.
  3. Public Equity Offerings: Raised approximately $75 million through public offering of common stock in January 2024 (10.87 million shares). Conducted under shelf registration with SEC.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Alector product offering

Product offering

Core offering

Alector is a clinical-stage biotechnology company that discovers and develops biologic therapeutics—including monoclonal antibodies, siRNA candidates, and enzyme replacement therapies—for neurodegenerative diseases such as frontotemporal dementia (FTD-GRN), Alzheimer's disease, Parkinson's disease, and Lewy body dementia. The pipeline is enabled by the proprietary Alector Brain Carrier (ABC) technology, which delivers therapeutic agents across the blood-brain barrier using receptor-mediated transcytosis. The company co-develops and co-commercializes its programs through partnerships with major pharmaceutical companies including GSK and AbbVie.

Product overview

Alector is a clinical-stage biotechnology company developing a pipeline of biologic drug candidates for neurodegenerative diseases. The company's product portfolio centers on immuno-neurology therapeutics targeting genetic pathways involved in neurodegeneration, including progranulin-elevating antibodies (latozinemab/AL001 and AL101), TREM2 agonistic antibodies (AL002), and next-generation candidates leveraging the proprietary Alector Brain Carrier (ABC) technology for enhanced blood-brain barrier delivery. The ABC platform supports multiple modality types including antibodies, siRNAs, and enzyme replacement therapies applied across Alzheimer's disease, frontotemporal dementia, Parkinson's disease, and other neurological conditions. Alector's clinical-stage candidates include latozinemab (AL001) for FTD-GRN and AL101 for Alzheimer's disease (with GSK partnership), while the preclinical pipeline features programs like AL037/AL137-ABC (anti-amyloid beta), AL050-ABC (GCase enzyme replacement), and siRNA-based programs targeting tau, alpha-synuclein, and NLRP3.

Differentiator

Problem solved

Functional benefit

Products and services

  • Latozinemab (AL001) Progranulin-elevating monoclonal antibody designed to restore diminished progranulin protein levels to normal ranges in patients with frontotemporal dementia due to GRN gene mutations (FTD-GRN), with the goal of slowing disease progression. Targeted at patients with this rare, rapidly progressing form of dementia.
  • AL101 (Nivisnebart / GSK4527226) Progranulin-elevating monoclonal antibody developed in collaboration with GSK for the treatment of early Alzheimer's disease, designed to increase progranulin levels in the brain as a potential strategy for slowing neurodegeneration.
  • AL002 TREM2 agonistic antibody for early Alzheimer's disease developed in partnership with AbbVie, targeting neuroinflammation and microglia function to restore immune and nerve cell activity in the brain.
  • AL037/AL137-ABC Proprietary anti-amyloid beta (Aβ) antibody paired with the Alector Brain Carrier (ABC) for the treatment of Alzheimer's disease. Designed to remove brain amyloid plaques with potential to reduce ARIA risk and enable subcutaneous delivery.
  • AL064/AL164-ABC Anti-tau siRNA combined with the Alector Brain Carrier, targeting tau pathology in Alzheimer's disease and other tauopathies by inhibiting tau mRNA and protein synthesis.
  • AL050-ABC Engineered GCase enzyme replacement therapy paired with the Alector Brain Carrier for GBA gene mutation carriers with Parkinson's disease and Lewy body dementia, designed to break down glucocerebroside that accumulates in neurons.
  • ADP062-ABC Anti-α-synuclein siRNA combined with the Alector Brain Carrier for Parkinson's disease, targeting α-synuclein pathology by inhibiting mRNA and protein synthesis.
  • ADP065-ABC Anti-NLRP3 siRNA combined with the Alector Brain Carrier targeting NLRP3-driven neuroinflammation in Alzheimer's disease and Parkinson's disease.
  • Alector Brain Carrier (ABC) technology platform Proprietary blood-brain barrier technology platform using receptor-mediated transcytosis to enhance brain penetration of therapeutic agents, enabling delivery of antibodies, siRNAs, and enzyme replacement therapies to the brain for the treatment of neurodegenerative diseases.

Quantifiable outcome

  • Latozinemab increased plasma progranulin levels in FTD-GRN patients (Phase 3 INFRONT-3 trial)
  • +5 more outcomes

Companies that use Alector

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Alector technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Alector partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, important and minor.

  • GlaxoSmithKline (GSK)coreStrategic or Co-development Partner · 1 January 2021Collaborative agreement with GSK to co-develop and co-commercialize progranulin franchise programs AL001 (latozinemab) and AL101. GSK paid $700 million upfront in 2021. Programs focused on treating frontotemporal dementia (FTD-GRN) and Alzheimer's disease by elevating progranulin levels.
  • AbbViecoreStrategic or Co-development Partner · 1 January 2017Partnership formed with AbbVie to co-develop Alector's Alzheimer's-focused lead program AL002. AL002 is a TREM2 agonistic antibody for treatment of early Alzheimer's disease. The partnership leverages AbbVie's global pharmaceutical development and commercialization capabilities.
  • AdimabimportantTechnology or Integration · 1 January 2015Strategic alliance with Adimab to access antibody technologies for drug discovery. This partnership provided Alector with access to Adimab's yeast-based antibody discovery platform, supporting the development of antibody therapeutics for neurodegenerative diseases.
  • Johnson & Johnson Innovation CenterminorStrategic or Co-development Partner · 1 January 2015Collaborative research agreement with Johnson & Johnson Innovation Center to fund one target through proof-of-concept in disease models. Part of Alector's early strategic partnerships to advance neurodegeneration research.

Scale indicators11 records

Recent moves8 records

Expansion highlights5 records

Alector competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Alector social profiles

Digital presence

Alector financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alector leadership team

Management profile

Number of profiles

Profiles13 records

Alector funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alector M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alector

What does Alector do?

Alector is a clinical-stage biotechnology company that discovers and develops biologic therapeutics—including monoclonal antibodies, siRNA candidates, and enzyme replacement therapies—for neurodegenerative diseases such as frontotemporal dementia (FTD-GRN), Alzheimer's disease, Parkinson's disease, and Lewy body dementia. The pipeline is enabled by the proprietary Alector Brain Carrier (ABC) technology, which delivers therapeutic agents across the blood-brain barrier using receptor-mediated transcytosis. The company co-develops and co-commercializes its programs through partnerships with major pharmaceutical companies including GSK and AbbVie.

Is Alector a public or private company?

Alector is a public company. It is classified as public and is currently operating.

When was Alector founded?

Alector was founded in 2013. It employs 101 to 250 people.

Where is Alector based?

Alector is headquartered in South San Francisco, United States, in the North America region.

How does Alector make money?

Three revenue lines are on record. Drug Development and Commercialization is the primary driver. The others are collaborative Development Agreements and public Equity Offerings.

Does Alector have an API?

No public API is recorded for Alector.

What industry is Alector in?

Alector's product category is Neurodegenerative Disease Therapeutics / Immuno-Neurology Biotechnology. Its primary akta.pro industry code is HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsAlector (NASDAQ:ALEC) Upgraded to Buy at Wall Street ZenWall Street Zen upgraded Alector from Hold to Buy, while other analysts have mixed ratings. The stock opened at $2.29, with a consensus price target of $4.62. The company reported Q3 EPS of $1.11, beating estimates.YahooAlector: Q3 Earnings SnapshotAlector Inc. reported third-quarter net income of $124.6 million, up from a loss a year earlier, with net income per share of $1.11. Revenue was $162.9 million, beating analyst estimates that expected a loss of 23 cents per share. Shares rose to $2.09, up from $1.26 a year ago.The future of tradingAlector Q3 net income swings to $124.6 millionAlector reported Q3 2026 net income of $124.6 million, reversing a prior-year loss of $34.7 million. Collaboration revenue rose to $162.9 million, and an exclusive global AL050 license with Genentech provides $100 million upfront and up to $1.17 billion in milestones. The company expects cash resources and offering proceeds to fund operations into the second half of 2029.Business & FinancialAlector Reports Third Quarter 2026 Financial Results And Provides Business UpdateAlector reported Q3 2026 net income of $124.6 million and $138.7 million in cash as of September 30, 2026. It entered an exclusive global license with Genentech for AL050, receiving $100 million upfront and eligible for up to $1.17 billion in milestones. The company expects its cash, the Genentech payment, and $75 million from an underwritten offering to fund operations into the second half of 2029.American Banking and Market NewsHead-To-Head Survey: CG Oncology (NASDAQ:CGON) & Alector (NASDAQ:ALEC)Alector beats CG Oncology on 9 of 14 factors, including higher revenue and earnings, and a higher consensus target price implying 102.85% upside versus 29.36% for CG Oncology. Alector also has stronger institutional ownership at 85.8% versus 26.6%.YahooWhat Alector Shareholders Got RightAlector's Q2 2026 revenue fell to $3.32 million from $7.874 million, while net loss narrowed to $22.99 million. The stock traded at $2.15, with a Fair Value above that level based on its ABC pipeline. The results tested both optimistic and pessimistic fair value assumptions.NasdaqAlector Consensus Price Target Increased by 15.38% to $4.59Alector's average one-year price target was raised to $4.59, up 15.38% from $3.98. The target is 104.45% above the latest closing price of $2.24, and the company's Q3 2026 earnings are scheduled for November 10, 2026.MarketBeatAlector (ALEC) Expected to Post Earnings on ThursdayAlector is expected to report Q3 2026 earnings on Thursday, November 5th, with analysts projecting a loss of $0.23 per share and revenue of $2.38 million. The company's last quarterly EPS was -$0.21, beating estimates, and revenue of $3.32 million exceeded the $1.71 million consensus. Analysts have a consensus target price of $4.62.MarketBeatAlector, Inc. (NASDAQ:ALEC) Stock Rated "Hold" by Wall Street AnalystsAlector's stock received an average 'Hold' rating from six brokerages, with a 1-year price objective of $4.62. The company reported Q2 EPS of -$0.21, beating estimates, and insiders sold 111,303 shares in the last 90 days. Analysts forecast a current-year loss of $0.47 per share.American Banking and Market NewsAlector, Inc. (NASDAQ:ALEC) Stock Has Consensus Target Price of $4.62 According to BrokeragesAlector's stock has a consensus "Hold" rating with a $4.62 price target, while CEO Arnon Rosenthal and CFO Neil Berkley sold shares on September 3rd. The company reported Q2 EPS of -$0.21, beating the -$0.23 estimate, with revenue of $3.32 million.